menu
    • menu
    [{"orgOrder":0,"company":"Traws Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Travatrelvir","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Traws Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Traws Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Traws Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Traws Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Travatrelvir","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Traws Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Traws Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Traws Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Traws Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Tivoxavir Marboxil","moa":"CEN","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Traws Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Traws Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Traws Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Traws Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Tivoxavir Marboxil","moa":"CEN","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Traws Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Traws Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Traws Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Traws Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tivoxavir Marboxil","moa":"CEN","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Traws Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Traws Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Traws Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Traws Pharma","sponsor":"Onconova Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Merger","leadProduct":"Tivoxavir Marboxil","moa":"CEN","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Traws Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Traws Pharma \/ Onconova Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Traws Pharma \/ Onconova Therapeutics"},{"orgOrder":0,"company":"Traws Pharma","sponsor":"OrbiMed Advisors","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Tivoxavir Marboxil","moa":"CEN","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Traws Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Traws Pharma \/ OrbiMed Advisors","highestDevelopmentStatusID":"6","companyTruncated":"Traws Pharma \/ OrbiMed Advisors"}]

    Find Clinical Drug Pipeline Developments & Deals by Traws Pharma

    Menu

    Traws Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Traws Pharma

                            U.S.A arrow
                            IMCAS Asia
                            Not Confirmed

                            Traws Pharma

                            U.S.A arrow
                            IMCAS Asia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tivoxavir Marboxil

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Traws Shows Positive Results for Tivoxavir Marboxil in Bird Flu Model

                            Details : TRX-100 (tivoxavir marboxil) is an inhibitor of highly conserved influenza protein, CAP-dependent endonuclease (CEN). It has demonstrated potent activity against highly pathogenic influenza strains.

                            Product Name : TRX100

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 03, 2025

                            Lead Product(s) : Tivoxavir Marboxil

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Traws Pharma

                            U.S.A arrow
                            IMCAS Asia
                            Not Confirmed

                            Traws Pharma

                            U.S.A arrow
                            IMCAS Asia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tivoxavir Marboxil

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Traws Pharma Completes Phase I Studies with Tivoxavir Marboxil for H5N1 Bird Flu

                            Details : TRX-100 (tivoxavir marboxil) is an inhibitor of highly conserved influenza protein, CAP-dependent endonuclease (CEN). It has demonstrated potent activity against highly pathogenic influenza strains.

                            Product Name : TRX100

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 23, 2025

                            Lead Product(s) : Tivoxavir Marboxil

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Traws Pharma

                            U.S.A arrow
                            IMCAS Asia
                            Not Confirmed

                            Traws Pharma

                            U.S.A arrow
                            IMCAS Asia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tivoxavir Marboxil

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Traws Pharma Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu

                            Details : TRX-100 (tivoxavir marboxil) is an inhibitor of highly conserved influenza protein, CAP-dependent endonuclease (CEN). It has demonstrated potent activity against highly pathogenic influenza strains.

                            Product Name : TRX100

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 23, 2024

                            Lead Product(s) : Tivoxavir Marboxil

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Traws Pharma

                            U.S.A arrow
                            IMCAS Asia
                            Not Confirmed

                            Traws Pharma

                            U.S.A arrow
                            IMCAS Asia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Travatrelvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Traws Pharma Reveals Positive Phase 1 Results for COVID Candidate Ratutrelvir

                            Details : Trwas Pharma's lead product TRX01 (ratutrelvir) is an orally-available protease inhibitor, which is being evaluated for the of treatment COVID19.

                            Product Name : TRX01

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 30, 2024

                            Lead Product(s) : Travatrelvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Traws Pharma

                            U.S.A arrow
                            IMCAS Asia
                            Not Confirmed

                            Traws Pharma

                            U.S.A arrow
                            IMCAS Asia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Travatrelvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy

                            Details : TRX01(travatrelvir) is an inhibitor targeting the SARS-CoV-2 viral main protease (MPro/3CL). It is being developed for the treatment of Covid 19.

                            Product Name : TRX01

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 05, 2024

                            Lead Product(s) : Travatrelvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Traws Pharma

                            U.S.A arrow
                            IMCAS Asia
                            Not Confirmed

                            Traws Pharma

                            U.S.A arrow
                            IMCAS Asia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tivoxavir Marboxil

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Onconova Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Onconova and Trawsfynydd Merge to Form Traws Pharma, a Virology and Oncology Company

                            Details : Through the merger, the company will focus on the clinical development of TRX100 (viroksavir), a CEN inhibitor. Currently, it is being evaluated in the Phase I clinical trial studies for influenza.

                            Product Name : TRX100

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            February 04, 2024

                            Lead Product(s) : Tivoxavir Marboxil

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Onconova Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Traws Pharma

                            U.S.A arrow
                            IMCAS Asia
                            Not Confirmed

                            Traws Pharma

                            U.S.A arrow
                            IMCAS Asia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tivoxavir Marboxil

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : OrbiMed Advisors

                            Deal Size : $28.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Onconova and Trawsfynydd Announce Business Combination to Form Traws Pharma

                            Details : The net proceeds will be used in the clinical development of TRX100 (viroksavir), a CEN inhibitor. Currently, it is being evaluating in the Phase I clinical trial studies for influenza.

                            Product Name : TRX100

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            February 04, 2024

                            Lead Product(s) : Tivoxavir Marboxil

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : OrbiMed Advisors

                            Deal Size : $28.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth